From: Rituximab for auto-immune alveolar proteinosis, a real life cohort study
Mean values | At Rituximab injection | After rituximab | p-value* | ||
---|---|---|---|---|---|
M3 | M6 | M12 | |||
Number of patients | 13 | 11 | 11 | 11 | Â |
D(A-a)O2 (mmHg) | 40 (31–57) | 43 (34–60) | 40 (31–56) | 35.9 (15–60) | 0.19 |
PaO2 (mmHg) | 68 (57–82) | 63 (55–70) | 65 (52–78) | 70 (49–92) | 0.51 |
Disease Severity Score | 2.7 (2–4) | 3.0 (2–4) | 2.8 (2–4) | 2.3 (1–5) | 0.44 |
VC (%predicted value) | 79 (36–100) | 78 (61–87) | 79 (50–100) | 84 (62–102) | 0.81 |
DLCO (% predicted value) | 54 (19–92) | 46 (30–86) | 50 (29–79) | 63 (35–97) | 0.38 |
Serum anti-GM-CSF | |||||
 ELISA (μg/mL)/Available | 99 (18–220)/8 | Na | 85 (19–187)/7 | 7.7 (3.1–158)/6 | 0.19 |
 Functional (titer)/Available | 853 (200–4000)/9 | Na | 831 (30–4000)/11 | 436 (0–1400)/8 | 0.21 |
CT-grade | 19.3 (12–28) | Na | 19.3 (13–28) | 17.3 (6–26) | 0.73 |